- ￥268 - 1088
- TargetMol
- USA
- T0078
- 2025年07月07日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
RT
- 保质期：
For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -97℃ for several months.
- 英文名：
Lapatinib
- 库存：
详询
- 供应商：
详询
- CAS号：
231277-92-2
- 规格：
5mg/10mg/25mg/50mg/1ml/10mM
| 规格： | 5mg | 产品价格： | ￥268.0 |
|---|---|---|---|
| 规格： | 10mg | 产品价格： | ￥398.0 |
| 规格： | 25mg | 产品价格： | ￥718.0 |
| 规格： | 50mg | 产品价格： | ￥1088.0 |
| 规格： | 1ml/10mM | 产品价格： | ￥458.0 |
ID：T0078
PURITY：0.985
Formula：C29H26ClFN4O4S
MolWt：581.06
Appearance：淡黄色粉末
Solubility：G4Soluble in DMSO
Bioactivity：Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug Capecitabine. Lapatinib is human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
Status：USP,INN
Pathways：Tyrosine Kinase/Adaptors; JAK/STAT Signaling
Target：EGFR inhibitor; HER2 inhibitor
Receptor：EGFR, ErbB2
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验称为HER2的蛋白，这类乳腺癌通常具有高度侵袭性。随着诸如曲妥珠单抗（trastuzumab ，商品名为Herceptin®）和拉帕替尼（lapatinib ，商品名为Tykerb®）一类的靶向性药物出现，它们也开始取得了良好的治疗效果。然而那些耐受曲妥珠单抗、复发性的，或不表达HER2的乳腺癌目前却仍然难于治疗。为了开发出乳腺癌的其他靶向性治疗策略，Lieberman与宋尔卫将研究焦点转向了一种称为RNA干扰 (RNAi) 的分子现象。RNAi是指通过小干扰RNAs(siRNAs)这类小片
ERBB4 Mutation Analysis: Emerging Molecular Target for Melanoma Treatment
to small-molecule inhibition with the dual-tyrosine kinase inhibitor lapatinib, and has recently also been implied in oncogenic glutamatergic signaling in melanoma. Mutations involving the ERBB4 gene act as “gain-of-function” mutations and predominantly
技术资料暂无技术资料 索取技术资料
